| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Association of gene variant type and location with breast cancer risk in the general population
|
Akamandisa, M.P.
|
|
|
36 |
8 |
p. 954-963
|
artikel
|
| 2 |
Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations
|
Turnbull, C.
|
|
|
36 |
8 |
p. 853-865
|
artikel
|
| 3 |
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody–drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
|
Zhang, J.
|
|
|
36 |
8 |
p. 934-943
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
36 |
8 |
p. iii
|
artikel
|
| 5 |
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)
|
Cherny, N.I.
|
|
|
36 |
8 |
p. 866-908
|
artikel
|
| 6 |
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy
|
Sahin, T.K.
|
|
|
36 |
8 |
p. 999
|
artikel
|
| 7 |
From the desert to the savannah, the future of combined MET-EGFR treatment
|
van den Heuvel, M.M.
|
|
|
36 |
8 |
p. 847-848
|
artikel
|
| 8 |
Maintenance treatment in sarcomas: who is it for?
|
Constantinidou, A.
|
|
|
36 |
8 |
p. 851-852
|
artikel
|
| 9 |
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa
|
Grimm, M.-O.
|
|
|
36 |
8 |
p. 988-998
|
artikel
|
| 10 |
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study ☆
|
Gratzke, C.
|
|
|
36 |
8 |
p. 964-975
|
artikel
|
| 11 |
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study ☆
|
Graff, J.N.
|
|
|
36 |
8 |
p. 976-987
|
artikel
|
| 12 |
Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial ☆
|
Penel, N.
|
|
|
36 |
8 |
p. 944-953
|
artikel
|
| 13 |
Reply to Letter to the Editor “Final results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy—PENELOPE-B” by Sahin and Guven
|
Loibl, S.
|
|
|
36 |
8 |
p. 1000-1001
|
artikel
|
| 14 |
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysis
|
Martín-Lluesma, S.
|
|
|
36 |
8 |
p. 909-919
|
artikel
|
| 15 |
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
|
de Marinis, F.
|
|
|
36 |
8 |
p. 920-933
|
artikel
|
| 16 |
Table of Contents
|
|
|
|
36 |
8 |
p. i-ii
|
artikel
|
| 17 |
The next-generation of nectin-4 targeted therapies
|
Pobel, C.
|
|
|
36 |
8 |
p. 849-850
|
artikel
|
| 18 |
The unjustified fear of erdafitinib-induced central serous retinopathy
|
Schauwvlieghe, P.-P.
|
|
|
36 |
8 |
p. 1001-1002
|
artikel
|
Tijdschrift beschrijving